Burning Rock Biotech Ltd (BNR) - Total Liabilities
Based on the latest financial reports, Burning Rock Biotech Ltd (BNR) has total liabilities worth $285.29 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BNR cash flow metrics to assess how effectively this company generates cash.
Burning Rock Biotech Ltd - Total Liabilities Trend (2017–2025)
This chart illustrates how Burning Rock Biotech Ltd's total liabilities have evolved over time, based on quarterly financial data. Check BNR financial resilience to evaluate the company's liquid asset resilience ratio.
Burning Rock Biotech Ltd Competitors by Total Liabilities
The table below lists competitors of Burning Rock Biotech Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aemetis Inc
NASDAQ:AMTX
|
USA | $566.67 Million |
|
Auna S.A.
NYSE:AUNA
|
USA | $5.47 Billion |
|
Putnam Master Intermediate Income Trust
NYSE:PIM
|
USA | $41.54 Million |
|
Bougainville Copper Limited
F:BOU1
|
Germany | €11.19 Million |
|
Whitestone Group
BR:ROCK
|
Belgium | €410.99K |
|
AptaBio Therapeutics Inc
KQ:293780
|
Korea | ₩22.51 Billion |
|
GREEN CROSS WellBeing Corporation
KQ:234690
|
Korea | ₩113.87 Billion |
|
SHIMAO SERV.HLDGS HD-01
F:5GO
|
Germany | €5.44 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Burning Rock Biotech Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Burning Rock Biotech Ltd worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Burning Rock Biotech Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Burning Rock Biotech Ltd (2017–2025)
The table below shows the annual total liabilities of Burning Rock Biotech Ltd from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $285.29 Million | -6.30% |
| 2024-12-31 | $304.48 Million | +12.11% |
| 2023-12-31 | $271.59 Million | -36.71% |
| 2022-12-31 | $429.13 Million | -0.96% |
| 2021-12-31 | $433.28 Million | +79.02% |
| 2020-12-31 | $242.02 Million | -86.08% |
| 2019-12-31 | $1.74 Billion | +78.16% |
| 2018-12-31 | $976.14 Million | +321.03% |
| 2017-12-31 | $231.85 Million | -- |
About Burning Rock Biotech Ltd
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction test… Read more